CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 168 enrolled
Drug / intervention
Tradipitant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02651714
NCT02651714Phase 2Completed
CompareCT.gov

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

Vanda Pharmaceuticals·interventional·Posted Jan 11, 2016·Updated Jun 13, 2024

In Brief

A Phase 2 clinical trial evaluating Tradipitant and Placebo for Atopic Dermatitis. Completed, enrolled 168 participants across 28 sites.

Detailed Summary

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with treatment-resistant pruritus diagnosed with atopic dermatitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 11, 2016
Enrollment StartJan 19, 2016
Primary CompletionAug 4, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.5 years ago

Interventions

Tradipitantdrug

Placebodrug